Blog

CAR-T 2.0? A split, universal and programmable system – FierceBiotech


FierceBiotech

CART 2.0? A split, universal and programmable system
FierceBiotech
Recent FDA approvals have validated the use of chimeric antigen receptor T cells (CAR-Ts) to fight blood cancers, but the technology is still far from perfect. Researchers working on CAR-T therapies have run into problems with patient relapse, toxicity
Senti scientific co-founder Wilson Wong designs the SUPRA — a new, high performance model CARTEndpoints News



all 2 news articles »

2018-04-26 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.